Skip to main content
. 2021 Jun 18;7(25):eabd8936. doi: 10.1126/sciadv.abd8936

Fig. 7. CCL21/CCR7 signaling is required for the suppression of DMBA-treated breast tumor growth and metastasis.

Fig. 7

(A) Spider plot of DMBA-treated PyMT breast tumor growth in Ccr7KO (Ccr7KO-A; n = 8) compared with WT (WT-A; n = 10) mice. **P < 0.005 starting at day 8. (B to D) T cell infiltrates in Ccr7KO-A compared with WT-A breast tumors demonstrated by (B) representative images of CD3- and CD8-stained tumor tissues, quantification of (C) CD3+ T cells and (D) CD8+ T cells within hpf images of Ccr7KO-A (n = 7) and WT-A (n = 4) breast tumors (**P < 0.01). (E and F) Metastasis burden in the lung of DMBA-exposed PyMT and PyMTCcr7KO mice demonstrated by (E) representative H&E-stained lung images (arrows point to metastatic foci) and (F) bar graph of the number of lung metastatic foci in each group. n = 5 in each group. Mann-Whitney U test was used. Graphs show means + SD. Scale bars, 100 μm (tumor) and 2 mm (lung).